Spotlight on Agalsidase Beta in Fabry Disease

ISSN： 1173-8804

Source： BioDrugs, Vol.21, Iss.4, 2007-01, pp. : 269-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agalsidase Alfa: A Review of its Use in the Management of Fabry Disease

By Keating Gillian M.

BioDrugs, Vol. 26, Iss. 5, 2012-10 ,pp. : 335-354

Adis International

Access to resources Recommend Favorite

Fabry Disease: Recognition and Management of Cutaneous Manifestations

By Möhrenschlager M. Braun-Falco M. Ring J. Abeck D.

American Journal of Clinical Dermatology, Vol. 4, Iss. 3, 2003-01 ,pp. : 189-196

Adis International

Access to resources Recommend Favorite

Spotlight on Infliximab in Crohn Disease and Rheumatoid Arthritis

By Siddiqui M. Asif A. Scott Lesley J.

BioDrugs, Vol. 20, Iss. 1, 2006-01 ,pp. : 67-70

Adis International

Access to resources Recommend Favorite

Progression of obstructive ventilatory disorder in Fabry disease: Only a matter of time?

THE CLINICAL RESPIRATORY JOURNAL, Vol. 12, Iss. 2, 2018-02 ,pp. : 832-834

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spotlight on Lanreotide Autogel ® in Acromegaly

By Croxtall Jamie D. Scott Lesley J.

BioDrugs, Vol. 22, Iss. 4, 2008-01 ,pp. : 275-277

Adis International

Access to resources Recommend Favorite